Wedbush raised the firm’s price target on Argenx to $560 from $519 and keeps an Outperform rating on the shares. Vygart revenue of $478M handily beat estimates and the firm looks forward to updates on ALKIVIA in myositis and BALLAD in bullous pemphigoid by year-end, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx upgraded to Buy at Deutsche after ‘solid return’ to U.S. form
- Argenx upgraded to Buy from Hold at Deutsche Bank
- argenx SE Flourishes with Strong Mid-Year Financials
- Argenx reports Q2 EPS 45c, consensus (98c)
- argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update